



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

08 August 2013
EMA/148540/2013 Rev 1
Patient Health Protection

Annex I

List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for substances related to nicotinic acid - acipimox

Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data

Procedure number: EMEA/H/A-31/1366



Member State in EEA	Marketing authorisation holder	INN	Product name	Strength	Pharmaceutical form	Route of administration
Austria	Pfizer Corporation Austria GmbH Floridsdorfer Hauptstraße 1 1210 Vienna Austria	acipimox	Olbetam - Kapseln	250 mg	capsule	oral use
Belgium	PFIZER S.A. Boulevard de la Plaine 17 1050 Ixelles Belgium	acipimox	Olbetam	250 mg	capsule	oral use
Denmark	Pfizer ApS, Lautrupvang 8, 2750 Ballerup Denmark	acipimox	Olbetam	250 mg	capsule	oral use
Hungary	Pfizer Gyógyszerkereskedelmi Kft. Alkotás u. 53. 1123 Hungary	acipimox	Olbetam 250 mg kemény kapszula	250 mg	capsule, hard	oral use
Italy	Pfizer Italia S.r.l. via Isonzo, 71 04100 Latina Italy	acipimox	OLBETAM	250 mg	capsule, hard	oral use
Luxembourg	PFIZER S.A. Boulevard de la Plaine 17 1050 Ixelles Belgium	acipimox	Olbetam	250 mg	capsule	oral use
The Netherlands	Pfizer B.V. Rivium Westlaan 142 2909 LD, Capelle a/d IJssel The Netherlands	acipimox	Olbetam, capsules 250 mg (RVG 13159)	250 mg	capsule	oral use

Member State in EEA	Marketing authorisation holder	INN	Product name	Strength	Pharmaceutical form	Route of administration
United Kingdom	Pfizer Limited Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom	acipimox	Olbetam Capsules	250mg	capsule	oral use